Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products

Several companies were authorized to treat COVID-19 patients with monoclonal antibodies within 1–2 years of the start of the pandemic. These products were discovered, developed, manufactured, clinically tested, and approved under emergency-use authorization at unprecedented speed. Pandemic urgency l...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Current opinion in biotechnology 2022-12, Vol.78, p.102798, Article 102798
Hauptverfasser:	Kelley, Brian, De Moor, Pam, Douglas, Kristen, Renshaw, Todd, Traviglia, Stacey
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - therapeutic use COVID-19 Humans Immunotherapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!